Department of Pediatrics, Steele Children's Research Center, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA.
J Clin Invest. 2011 Jun;121(6):2149-52. doi: 10.1172/JCI58025. Epub 2011 May 23.
Preclinical studies with probiotics continue to unravel mechanisms of cytoprotection and suggest that approaches utilizing microbial products as therapeutics in acute and chronic gastrointestinal disorders could be effective. However, clinical trials using these bacteria have thus far been inconsistent. In this issue of the JCI, Yan et al. describe a novel mechanism of cytoprotection by p40, a soluble product of Lactobacillus rhamnosus GG, mediated via EGFR. The efficacy of p40 in three models of chemically induced colitis indicates tremendous therapeutic potential, though this finding will need to be verified in human patients.
益生菌的临床前研究不断揭示细胞保护的机制，并表明利用微生物产物作为治疗急性和慢性胃肠道疾病的方法可能是有效的。然而，迄今为止，使用这些细菌的临床试验结果并不一致。在本期 JCI 中，Yan 等人描述了鼠李糖乳杆菌 GG 的可溶性产物 p40 通过 EGFR 介导的细胞保护的新机制。p40 在三种化学诱导结肠炎模型中的疗效表明其具有巨大的治疗潜力，但这一发现需要在人类患者中得到验证。
